U.S. markets open in 6 hours 16 minutes

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3673-0.0077 (-2.05%)
At close: 04:00PM EST
0.3677 +0.00 (+0.11%)
After hours: 07:03PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.3750
Bid0.0000 x 1100
Ask0.0000 x 800
Day's Range0.3600 - 0.3799
52 Week Range0.3550 - 2.9950
Avg. Volume4,559,450
Market Cap67.133M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ITRM

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Iterum Therapeutics plc
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    15 days agoMorningstar
View more
  • Simply Wall St.

    Is Iterum Therapeutics (NASDAQ:ITRM) Weighed On By Its Debt Load?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • Zacks

    Iterum Therapeutics PLC (ITRM) Could Find Support Soon, Here's Why You Should Buy the Stock Now

    Iterum Therapeutics PLC (ITRM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

  • Benzinga

    15 Stocks Moving in Friday's Pre-Market Session

    Gainers Progenity, Inc. (NASDAQ: PROG) rose 33% to $2.02 in pre-market trading after jumping over 40% on Thursday. Iterum Therapeutics plc (NASDAQ: ITRM) rose 25.1% to $0.6984 in pre-market trading after dropping over 8% on Thursday. QuickLogic Corporation (NASDAQ: QUIK) rose 14.7% to $6.15 in pre-market trading. QuickLogic reported a strategic investment by current shareholders. The company said it expects Q3 revenue of $3.8 million to $3.9 million. Paltalk, Inc. (NASDAQ: PALT) rose 12.3% to $1